 |
|
Study produces conflicting findings on the use of anti-anemia drug in cancer patients
April 17, 2007LOS ANGELES - Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
The drug, darbepoetin alfa (DA) is a synthetic form of erythropoietin, a hormone that signals the formation of new red blood cells from within the bone marrow. DA is commonly used as a means of combating anemia in cancer patients who are also receiving chemotherapy. Anemia in cancer patients can result from either chemotherapy or the cancer itself, and it has a measurable effect on quality of life and overall cancer survival.
While some cancer patients not undergoing chemotherapy are also given DA, previous placebo-controlled studies did not show that darbepoetin significantly reduced transfusion risk.
"While the study was not specifically designed to study survival rates, our results indicate a statistically significant decrease in patients given the drug versus those who were given placebo," said John Glaspy, M.D., professor at the University of California, Los Angeles School of Medicine. "Since erythropoietic agents are sometimes used in the U. S. to treat anemia and reduce transfusion risk in patients not on chemotherapy, these results are of concern to the research and clinical cancer communities."
The trial was designed to examine the ability of darbepoetin to reduce the need for blood transfusions in patients with active cancer not undergoing chemotherapy. The trial, held in clinical sites throughout North America, Europe and Australia was supported by the drug's manufacturer, Amgen.
Approximately 1,000 people were enrolled in the study, which was open to patients with most forms of cancer, except myeloid or acute leukemia and Burkitt's or lymphoblastic lymphoma. The most common cancers were non-small cell lung, breast and prostate cancer, with 82 percent of patients in disease stage III or IV. Patients were randomly assigned to receive either DA or a placebo, and given a weekly dose until week 16 or until the patient required a blood transfusion. The patients were then given an end-of-study examination at week 19, with two years of follow up to evaluate survival. During the study, researchers monitored each patient's hemoglobin level, an indicator of red blood cell production. Darbepoetin was withheld if the patient's hemoglobin count exceeded 13 grams per deciliter.
According to the researchers, fewer patients in the darbepoetin group required transfusions during the study, but the overall difference between the darbepoetin and placebo groups was not statistically significant. Subsequent analysis also showed a statistically significant increase in patient deaths - during the trial and in the follow up - amid the darbepoetin arm of the trial versus the placebo group, with 136 darbepoetin patient deaths versus 94 in the placebo group. Researchers say the trial was not designed to focus on survival, prognostic factors were not balanced at baseline and no specific study procedures were undertaken to determine the exact cause of death for these patients, beyond investigator attribution.
One confounding aspect of these study results was the different reactions among patients in the darbepoetin group, says Glaspy. When treated with darbepoetin, patients with kidney, prostate, or stomach cancers, non-Hodgkin's lymphoma, or multiple myeloma appeared to have worse survival outcomes. However, the opposite was seen among patients with breast, colon, ovarian, or cervical cancer. Indeed, many of these patients also achieved higher hemoglobin counts (yet still within the study's safety parameters). Survival rates were also better for patients in either group who did not need to receive transfusions.
"People with cancers like myeloma and lymphoma did substantially worse than people with diseases like breast cancer, for example," Glaspy said.
When the researchers notified Amgen of their preliminary results, the company issued a warning to doctors and informed the Food and Drug Administration as to the results of the trial. Subsequently, the manufacturer and FDA agreed to a "black box" warning for doctors about the drug's safety in this particular circumstance. "Certainly, the first concern is about safety, although nobody wants to see an increase in transfusions among patients already on the medication and doing well," said Glaspy.
"The findings will pose a particular puzzle to cancer researchers, as the exact mechanisms behind the observed decrease in patient survival is not clear," Glaspy said. "Likewise, we'll need to resolve these data in light of evidence that darbepoetin offers benefits for patients with certain types of cancer when used within chemotherapy. There are no obvious reasons for this discrepancy."
American Association for Cancer Research
"While the study was not specifically designed to study survival rates, our results indicate a statistically significant decrease in patients given the drug versus those who were given placebo," said John Glaspy, M.D., professor at the University of California, Los Angeles School of Medicine. "Since erythropoietic agents are sometimes used in the U. S. to treat anemia and reduce transfusion risk in patients not on chemotherapy, these results are of concern to the research and clinical cancer communities."
The trial was designed to examine the ability of darbepoetin to reduce the need for blood transfusions in patients with active cancer not undergoing chemotherapy. The trial, held in clinical sites throughout North America, Europe and Australia was supported by the drug's manufacturer, Amgen.
Approximately 1,000 people were enrolled in the study, which was open to patients with most forms of cancer, except myeloid or acute leukemia and Burkitt's or lymphoblastic lymphoma. The most common cancers were non-small cell lung, breast and prostate cancer, with 82 percent of patients in disease stage III or IV. Patients were randomly assigned to receive either DA or a placebo, and given a weekly dose until week 16 or until the patient required a blood transfusion. The patients were then given an end-of-study examination at week 19, with two years of follow up to evaluate survival. During the study, researchers monitored each patient's hemoglobin level, an indicator of red blood cell production. Darbepoetin was withheld if the patient's hemoglobin count exceeded 13 grams per deciliter.
According to the researchers, fewer patients in the darbepoetin group required transfusions during the study, but the overall difference between the darbepoetin and placebo groups was not statistically significant. Subsequent analysis also showed a statistically significant increase in patient deaths - during the trial and in the follow up - amid the darbepoetin arm of the trial versus the placebo group, with 136 darbepoetin patient deaths versus 94 in the placebo group. Researchers say the trial was not designed to focus on survival, prognostic factors were not balanced at baseline and no specific study procedures were undertaken to determine the exact cause of death for these patients, beyond investigator attribution.
One confounding aspect of these study results was the different reactions among patients in the darbepoetin group, says Glaspy. When treated with darbepoetin, patients with kidney, prostate, or stomach cancers, non-Hodgkin's lymphoma, or multiple myeloma appeared to have worse survival outcomes. However, the opposite was seen among patients with breast, colon, ovarian, or cervical cancer. Indeed, many of these patients also achieved higher hemoglobin counts (yet still within the study's safety parameters). Survival rates were also better for patients in either group who did not need to receive transfusions.
"People with cancers like myeloma and lymphoma did substantially worse than people with diseases like breast cancer, for example," Glaspy said.
When the researchers notified Amgen of their preliminary results, the company issued a warning to doctors and informed the Food and Drug Administration as to the results of the trial. Subsequently, the manufacturer and FDA agreed to a "black box" warning for doctors about the drug's safety in this particular circumstance. "Certainly, the first concern is about safety, although nobody wants to see an increase in transfusions among patients already on the medication and doing well," said Glaspy.
"The findings will pose a particular puzzle to cancer researchers, as the exact mechanisms behind the observed decrease in patient survival is not clear," Glaspy said. "Likewise, we'll need to resolve these data in light of evidence that darbepoetin offers benefits for patients with certain types of cancer when used within chemotherapy. There are no obvious reasons for this discrepancy."
American Association for Cancer Research
Blood Transfusion Current Events and Blood Transfusion News RSSHybrid revascularization effective for left main coronary blockages
The left main coronary artery provides most of the blood to the heart, and current guidelines call for patients with blockages in this artery to undergo bypass surgery.
Restrictions on female plasma may not be warranted
Three years after the U.S. blood banking industry issued recommendations that discourage transfusing plasma from female donors because of a potential antibody reaction, Duke University Medical Center researchers discovered that female plasma actually may have advantages.
IOM report recommends steps to tackle hepatitis B and C
Stepped-up vaccination requirements, a boost in resources for prevention and treatment, and a public awareness campaign similar to the effort that dispelled the stigma of HIV/AIDS are needed to curb the health threats posed by hepatitis B and hepatitis C, says a new report from the Institute of Medicine.
Anemia drug not helpful for kidney disease patients
An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.
MRI helps detect life-threatening pregnancy complication
A study presented today at the annual meeting of the Radiological Society of North America (RSNA) revealed that MRI is a highly accurate means of identifying placenta accreta, a potentially life-threatening and increasingly common condition that is the leading cause of death for women just before and after giving birth.
Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Better blood screening process needed to prevent babesiosis transmission
Babesiosis is a potentially dangerous parasitic disease transmitted by ticks and is common in the Northeast and the upper Midwest. Babesia lives inside of red blood cells, meaning it can also be transmitted through a blood transfusion from an infected but otherwise asymptomatic blood donor.
Study dispels myth that new residents cause increase in medical errors in July
New research published in the September issue of the Journal of the American College of Surgeons challenges the widely held belief that more medical errors occur in teaching hospitals during the month of July due to the influx of new graduates from medical and nursing schools - also known as the "July Phenomenon."
Blood transfusion study: Less is more
A new study suggests that blood transfusions for hospitalized cardiac patients should be a last resort because they double the risk of infection and increase by four times the risk of death.
Hepatitis C infection: treatment options equally effective, likelihood of success known early on
Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.
More Blood Transfusion Current Events and Blood Transfusion News Articles
 |
Modern Blood Banking And Transfusion Practices by Denise M. Harmening (Author), Denise M. Harmening (Editor) Modern Blood Banking and Transfusion Practices continues to set the standard for teaching and learning modern blood banking. Thorough, yet concise, the fifth edition begins with a review of basic science, plus the history of blood preservation, and continues to provide students with a working knowledge of modern blood banking as it focuses on the how and why of transfusion practice, presenting a perfect "crossmatch" of theory and practice. |
|
Blood Transfusion by Simti Servizi Srl | |
 |
Transfusion by Cold Blood, Lydia Pense Cold Blood was originally signed in 1969 by Bill Graham to his own label and went on to record six albums before disbanding in the late 1970s. The band was revived in the late 1980s and the current lineup started to coalesce in the mid-‘90s under the direction of guitarist Steve Dunne, which culminated in a triumphant return to the Fillmore in 1998. In 2001, DIG Music released Vintage Blood: Live! 1973, a previously unreleased powerhouse collection of songs including their signature version of "You Got Me Hummin’," recorded in an intimate studio setting before a live audience.At the same time, former Cold Blood member Skip Mesquite, who had a number of songs he’d written and thought would be well- suited for Lydia, came in contact with DIG Music. Armed with these great new... |
 |
Saving Lives with Serum Albumin. Doctors today know the riddle of why an injured man, his wounds perfectly treated, may still not recover. He may be a victim of "shock", a dangerous trend toward failure of blood circulation. Unless this trend is promptly reversed, the effect is fatal. Now doctors have anew tool to fight shock - a tool newer than blood transfusions or plasma. This discovery, concentrated Serum Albumin, when used in shock cases, actually draws fluid from the body tissues into the circulation to make up the loss. This Human Serum Albumin is made from the blood you donate. Squibb Laboratories were among the first to produce Serum Albumin for our Armed Forces. ..... 1944 Squibb Ad, A5132. This Item is an original Magazine ad, taken from a vintage magazine of the year indicated. The ad is suitable for framing and displaying in your home or office. The scan of this item was taken through plastic film, however it is an accurate representation of the item. The nominal size is 10.5 inches by 14 inches. |
 |
Blood Transfusion in Hospital Iv Drip Photographic Poster Print, 18x24 by AllPosters.com Blood Transfusion in Hospital Iv Drip is digitally printed on archival photographic paper resulting in vivid, pure color and exceptional detail that is suitable for any museum or gallery display. Finding that perfect piece to match your interest and style is easy and within your budget! |
 |
Down To The Bone (Album Version) Cold Blood (Primary Contributor) |
 |
Transfusion Alternatives Documentary Series Note: This DVD is in English, French, German, Italian, Japanese, Portuguese, Russian, Spanish. Physicians around the world are now successfully treating patients who desire to have medical care without blood transfusions. With the help of many recognized experts, this series explores the medical, legal, and ethical principles surrounding transfusion alternatives. |
 |
Jorgensen Blood Bag, Dry, 50 - 150ml, For Animal Use by Jorgensen Laboratories Features of the Jorgensen Blood Bag: A wide range of Blood Transfusion Products allows for all species to be recipients of blood transfusion medicine. Canines tolerate standard human transfusion products. Feline patients require much smaller 50-150ml bags. Equine patients need 1-4 liter bags to do the job adequately. Blood component therapy is an expanding field. Plasma and concentrated RBCs can be separated, and specific therapeutic modalities can be implemented. The addition of transfer bags and dry collection bags make this an easy procedure. Provide your own anticoagulant for the use of these blood bags. Two spike ports with donor tubing with Y" injection port. Includes directions for use. The product referenced on this detail page is sold be Each. |
 |
No Blood ~ Medicine Meets the Challenge Since the AIDS and hepatitis scares of the 1980's, the public has become increasing aware of the very real risks associated with blood transfusions. When facing surgery, growing numbers of patients are demanding "No blood!" Among these are Jehovah's Witnesses, who refuse blood transfusions for religious reasons. In recent years, medical science has developed safe, effective nonblood alternatives in virtually every subspecialty of medicine. An improved standard of care for all patients has thus been made possible. This half-hour documentary, "No Blood -- Medicine Meets the Challenge", presents case histories along with interviews of health-care workers, legal experts, and leading medical authorities. Actual medical footage and computer animations help viewers understand what nonblood... |
 |
Blood Banking and Transfusion Medicine: Basic Principles and Practice by Christopher D. Hillyer MD (Author), Leslie E. Silberstein MD (Author), Paul M. Ness MD (Author), Kenneth C. Anderson MD (Author), John D. Roback MD PhD (Author) Ever since the discovery of blood types early in the last century, transfusion medicine has evolved at a breakneck pace. This second edition of Blood Banking and Transfusion Medicine is exactly what you need to keep up. It combines scientific foundations with today's most practical approaches to the specialty. From blood collection and storage to testing and transfusing blood components, and finally cellular engineering, you'll find coverage here that's second to none. New advances in molecular genetics and the scientific mechanisms underlying the field are also covered, with an emphasis on the clinical implications for treatment. Whether you're new to the field or an old pro, this book belongs in your reference library. Integrates scientific foundations with clinical relevance to... |
| © 2010 BrightSurf.com |